利福平联合美罗培南+阿莫西林/克拉维酸对耐利福平肺结核早期杀菌活性:2a期研究
该2a期随机试验纳入52例耐利福平肺结核患者,比较美罗培南+阿莫西林/克拉维酸联合或不联合利福平的14天早期杀菌活性。结果显示两组CFU下降和TTP延长无统计学显著差异,美罗培南药代动力学相似,利福平MIC未被美罗培南显著降低。
要点
- 加用利福平未增强美罗培南+阿莫西林/克拉维酸对RR-TB的短期杀菌活性
- 两组14天CFU EBA中位预测值分别为1.33和1.20 log10 CFU/mL,差异无统计学意义
- 美罗培南未显著降低利福平MIC,药代动力学两组相似
核心结论
- 在耐利福平肺结核患者中,美罗培南+阿莫西林/克拉维酸加用利福平未增强短期抗菌活性。
研究设计与样本
- 2a期随机试验纳入52例耐利福平肺结核患者,38例完成试验,随机分为M-AC-R组和M-AC组。
主要发现
- M-AC-R组14天CFU EBA中位预测值为1.33 log10 CFU/mL(95%预测区间-0.15至3.64),M-AC组为1.20(0.05-2.66)。
- M-AC-R组TTP增加0.220 log10小时(95%预测区间0.098-0.551),M-AC组增加0.216(0.126-0.505),两组无统计学显著差异。
- 美罗培南药代动力学两组相似,利福平MIC未因美罗培南而显著降低。
临床怎么用
- 基于本2a期试验,不推荐在美罗培南+阿莫西林/克拉维酸方案中加用利福平以增强早期杀菌活性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In vitro, meropenem is shown to restore the activity of rifampicin in rifampicin-resistant Mycobacterium tuberculosis strains. This phase 2a trial aimed to determine if addition of rifampicin increases the early bactericidal activity (EBA) of meropenem plus amoxicillin/clavulanate in patients with rifampicin-resistant tuberculosis (RR-TB). METHODS: Individuals with RR-TB were randomized to either 2 g meropenem infusion 3 times daily plus amoxicillin/clavulanate 500 mg/125 mg orally 3 times daily with 20 mg/kg rifampicin orally once daily (M-AC-R arm) or the same treatment without rifampicin (M-AC). Sputum samples were collected at baseline and throughout the 14-day treatment. Colony-forming unit (CFU) and time-to-positivity (TTP) data were analyzed using nonlinear mixed-effects modeling. Plasma samples at day 13 were used to derive rifampicin and meropenem pharmacokinetic parameters using noncompartmental analysis. Rifampicin minimum inhibitory concentrations (MICs) were determined from baseline sputum isolates with and without meropenem. RESULTS: Of the 52 participants enrolled, 38 participants completed the trial. The majority (67%) were male, and the median age was 37 years. The median (95% prediction interval) predicted 14-day EBA in CFU was 1.33 (-0.15 to 3.64) and 1.20 (0.05-2.66) log10 CFU/mL, and TTP increased by 0.220 (0.098-0.551) and 0.216 (0.126-0.505) log10 hours for the M-AC-R and M-AC arms, respectively. No statistically significant difference was found between the 2 arms. Meropenem pharmacokinetics were similar in both arms, and rifampicin MICs were not meaningfully reduced by meropenem. CONCLUSIONS: Adding rifampicin to meropenem plus amoxicillin/clavulanate did not enhance short-term antibacterial activity in patients with RR-TB.
引用
- de Jager V, Mockeliunas L, You H, et al. A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary Tuberculosis. Clin Infect Dis. 2025. PMID: 40455216. doi:10.1093/cid/ciaf276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。